REFERENCES
1. Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep. 1836;1:476-85. Available from https://catalog.hathitrust.org/Record/010088303 [Last accessed on 5 Mar 2025].
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
3. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
5. Genua I, Iruzubieta P, Rodríguez-Duque JC, Pérez A, Crespo J. NAFLD and type 2 diabetes: a practical guide for the joint management. Gastroenterol Hepatol. 2023;46:815-25.
6. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
7. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
9. Hong S, Sun L, Hao Y, et al. From NAFLD to MASLD: when metabolic comorbidity matters. Ann Hepatol. 2024;29:101281.
10. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-55.
11. Shang Y, Grip ET, Modica A, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care. 2024;47:978-85.
12. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44:1051-60.
13. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:122.
14. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25:375-84.
15. Lombardi R, Airaghi L, Targher G, et al. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int. 2020;40:347-54.
16. Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies. Int J Endocrinol. 2022;2022:8463640.
17. Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000-8.e3.
18. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr. 2010;64:16-22.
19. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol. 2024;80:e61-2.
20. Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol. 2023;79:1524-41.
21. Duseja A, De A, Wong V. Special population: lean nonalcoholic fatty liver disease. Clin Liver Dis. 2023;27:451-69.
22. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases. Med Sci Monit. 2024;30:e945198.
23. Park H, Yoon EL, Kim M, Cho S, Nah EH, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): considerable proportions of MAFLD are metabolic healthy. Clin Gastroenterol Hepatol. 2023;21:1041-9.e3.
24. Huang J, Kumar R, Wang M, Zhu Y, Lin S. MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant? J Hepatol. 2020;73:1265-7.
25. Meroni M, Longo M, Paolini E, et al. MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. J Intern Med. 2022;291:374-6.
26. Sookoian S, Rotman Y, Valenti L. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clin Gastroenterol Hepatol. 2024;22:2177-87.e3.
27. Thakral N, Desalegn H, Diaz LA, et al. A precision medicine guided approach to the utilization of biomarkers in MASLD. Semin Liver Dis. 2024;44:273-86.
28. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000.
29. Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74:1455-71.
30. Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918-30.
32. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81:930-40.
33. Whitfield JB, Schwantes-An TH, Darlay R, et al; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol. 2022;76:275-82.
34. Burton R, Fryers PT, Sharpe C, et al. The independent and joint risks of alcohol consumption, smoking, and excess weight on morbidity and mortality: a systematic review and meta-analysis exploring synergistic associations. Public Health. 2024;226:39-52.
35. Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clin Med. 2018;18:s54-9.
36. Nasr P, Wester A, Ekstedt M, et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol. 2024;22:1048-57.e2.
37. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
38. Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int. 2023;17:350-6.
39. Santos-Laso A, Gutiérrez-Larrañaga M, Alonso-Peña M, et al. Pathophysiological mechanisms in non-alcoholic fatty liver disease: from drivers to targets. Biomedicines. 2021;10:46.
41. De Filippo O, Di Pietro G, Nebiolo M, et al. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis. Eur J Clin Invest. 2024;54:e14188.
42. Solomon A, Negrea MO, Cipăian CR, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study. Healthcare. 2023;11:2696.
43. Kang MK, Song JE, Loomba R, et al. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification. Sci Rep. 2024;14:22917.
44. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44:1567-74.
45. Ciardullo S. The MAFLD-MASLD debate: does cardiovascular risk prediction define the winner? Liver Int. 2024;44:1564-6.
46. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 2024;44:1762-7.
47. Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59:150-6.
48. Chrysavgis L, Cholongitas E. From NAFLD to MASLD: what does it mean? Expert Rev Gastroenterol Hepatol. 2024;18:217-21.
49. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026-39.
50. Wong VWS, Zelber-Sagi S, Cusi K, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42:2377-89.
51. Eskridge W, Cryer DR, Schattenberg JM, et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023;12:6216.
52. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79:1393-400.
53. Iruzubieta P, Santos-Laso A, Arias-Loste MT, Calleja JL, Crespo J. Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings. J Hepatol. 2024;80:e121-3.
54. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54-6.
55. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
56. Lazarus JV, Mark HE, Allen AM, et al; Healthy Livers, Healthy Lives Collaborators. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024;79:502-23.
57. Hagström H, Adams LA, Allen AM, et al. The future of international classification of diseases coding in steatotic liver disease: an expert panel Delphi consensus statement. Hepatol Commun. 2024;8:e0386.
58. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2024;Epub ahead of print.
59. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
60. Puhl RM. Weight stigma and barriers to effective obesity care. Gastroenterol Clin North Am. 2023;52:417-28.
61. Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity. Liver Int. 2021;41:2295-307.
62. Carol M, Pérez-Guasch M, Solà E, et al; LiverHope Consortium Investigators. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One. 2022;17:e0265153.
63. Younossi ZM, Alqahtani SA, Alswat K, et al; Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80:419-30.
64. Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024;6:101066.
65. Méndez-Sánchez N, Pal SC, Fassio E, Díaz-Ferrer J, Prado-Robles JA. MAFLD: perceived stigma-a single-center Mexican patient survey. Hepatol Int. 2023;17:507-8.
66. Shiha G, Korenjak M, Casanovas T, et al. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022;77:1717-9.
67. Ramírez-Mejía MM, Qi X, Abenavoli L, Méndez-Sánchez N. The myth of the stigma of fatty liver: what does the evidence show? Ann Hepatol. 2024;29:101535.
68. Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65-72.
69. Sun M, Rahman AA, Yao VJH. Screening for social determinants of health in underserved populations to promote better outcomes in ALD and MASLD. Clin Gastroenterol Hepatol. 2025;23:379-80.
70. Kim RG, Ballantyne A, Conroy MB, Price JC, Inadomi JM. Screening for social determinants of health among populations at risk for MASLD: a scoping review. Front Public Health. 2024;12:1332870.
71. Lazarus JV, Mark HE, Anstee QM, et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60-78.
72. Lazarus J V, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76:771-80.
73. Alboraie M, Fouad Y, Eslam M. Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective? Hepatology. 2024;80:E42-3.
74. Hoofnagle JH, Doo E. Letter to the editor: a multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;79:E91-2.
75. Fouad Y, Alboraie M, El-Shabrawi M, Zheng MH. Letter to the editor: how F to S turned the premature to be mature? Hepatology. 2024;79:E157-8.
77. Alboraie M, Tanwandee T, Xu X, et al. Global multi-societies endorsement of the MAFLD definition. Ann Hepatol. 2024;29:101573.
